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Abstract: Many plant-based bioactive compounds have been serving as the origin of drugs since long ago and 
many of them have been proven to have medicinal value against various chronic diseases, including, cancer, 
arthritis, hepatic diseases, type-2 diabetes and cardiovascular diseases. However, their clinical applications have 
been limited due to their poor water solubility, stability, low bioavailability and extensive transformation due to 
the first-pass metabolism. The applications of nanocarriers have been proven to be able to improve the delivery of 
bioactive phytoconstituents, resulting in the enhancement of various pharmacokinetic properties and thereby 
increasing the therapeutic value of phytoconstituents. These biocompatible nanocarriers also exert low toxicity to 
healthy cells. This review focuses on the uses and applications of different types of nanocarriers to enhance the 
delivery of phytoconstituents for the treatment of various chronic diseases, along with comparisons related to 
bioavailability and therapeutic efficacy of nano phytoconstituents with native phytoconstituents. 
Keywords: Phytoconstituents, nanocarriers, bioavailability, chronic diseases, nanoparticles, nanomedicine. 
1. INTRODUCTION 
 Plants have, from time immemorial, remained as a diverse 
source for the discovery of various forms of therapeutic agents [1]. 
Plant-derived medicine is believed to be a safer alternative to con-
ventional medicine without compromising its effectiveness in 
treatment [2–4]. Some plants have a protective effect on human 
cells, which can minimise the damage caused by the treatment [5–
7]. However, plant-derived medicine faces challenges in terms of 
drug delivery and targeted effects with a reduced availability at the 
desired site. This may be attributed to its poor stability and solubil-
ity, along with the rapid elimination from the body systems [8–10]. 
This demands an immediate need for an efficient delivery system to 
deliver the active constituents specifically to the desired site of 
action in a sustained manner while keeping the toxicity effects at its 
minimum [11,12]. 
 The rise of pharmaceutical technology has led to the develop-
ment of nanocarriers as the principal drug transport agents. Nano-
carriers are drug transport modules with submicron particle size, 
generally below 500 nm [13,14]. Owing to their small size, they 
have the ability to improve the properties of the drug and carry the  
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drug to the specific target site. It has been established that the 
nanoparticle drug carriers are able to accumulate specifically at 
target sites owing to their passive targeting mechanisms, by con-
tinuously supplying the encapsulated agent to the site [15]. Thus, 
nanocarriers are able to improve the properties and effects of plant-
derived medicine, producing a safer and more effective treatment 
option, with the combination of natural products and nanotechnol-
ogy [16]. 
 Different nanocarriers are employed based on their properties 
and the mode of treatment involved. Common nanomaterials in-
clude liposomes, solid lipid nanoparticles and metal nanoparticles, 
such as gold and silver nanoparticles [17]. Liposomes are spherical 
vesicles consisting of at least one phase of the lipid layer and spon-
taneously assemble into bilayers once in contact with water. Hence, 
liposomal systems can be employed to encapsulate drugs made of 
both lipophilic and hydrophilic compounds, making them the ideal 
carrier for a diverse range of drugs [18–20]. Metal nanoparticles, 
such as gold and silver nanoparticles, are often used in the man-
agement of wounds, due to their known anti-microbial and anti-
inflammatory effects [21]. Silver exerts an anti-bacterial effect by 
attaching thiol groups to enzymes, which are also required for respi-
ratory chains of bacteria [22,23]. Silver nanoparticles take advan-
tage of the high-surface-to-volume ratio of nanoparticles to increase 
the contact area to the bacteria, resulting in a higher amount of sil-
ver ions to perform its bactericidal activities [24]. In addition to 
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that, solid lipid nanoparticles are another type of colloidal nano-
sized delivery system which is made up of surfactant-stabilised 
lipids that remain in a solid-state at room and body temperature. 
They are generally stable and are capable of targeted delivery and 
carry lipophilic and hydrophilic drugs [25,26]. Furthermore, 
niosomes are vesicles made of non-ionic surfactant with cholesterol 
incorporated as an excipient. They have a high penetrating ability 
and are stable to be used in body systems [27–29]. Those men-
tioned earlier are some of the common nanocarriers, but other types 
of nanocarriers also will be discussed in this review, along with 
their applications and therapeutic uses.  
2. ADVANTAGES OF NANOCARRIERS 
 Different natural phytoconstituents have comprehensive bio-
logical activities and broad therapeutic efficacies in chronic dis-
eases. The biggest advantage of using phytoconstituents is that they 
treat adverse effects significantly and effectively as compared to 
any other dosage forms. The physiochemical properties such as low 
solubility, low permeation and non-objective efficacy at the active 
site are the common barriers to their therapeutic effectiveness. Dif-
ferent nanocarrier based approaches are used to resolve these obsta-
cles, thereby, providing a sustained and consistent therapeutic tar-
geting at required concentrations to enhance the therapeutic effec-
tiveness at the active site [9,10,30–32]. 
 The use of nanocarriers (Figure 1) for plant-derived medicines 
has provided a huge benefit by enhancing their bioavailability and 
selectivity towards the target site, resulting in a more effective and 
less harmful treatment outcome [33]. Nanocarriers can be designed 
to release drugs in a controlled manner from their reservoirs. This 
will maintain a constant amount of drug in the targeted site and, 
subsequently, reduce the frequency of drug administration required 
[34]. Not only do nanocarriers achieve a more effective, selective 
and safer therapeutic effect, but they also offer a more convenient 
and better compliance when it comes to treatment options, to major-
ity of the patients [35]. 
3. LIMITATIONS OF NANOCARRIERS 
 Comprehensive knowledge of health and toxicological issues is 
important to exploit the potential and usability of nanocarriers. 
Furthermore, this becomes essential to overcome the limitations of 
the nanocarrier being used. The so-called therapeutic ratio or index, 
which lies between the dose required for clinical effectiveness and 
the dose-inducing side effects (toxicity), can be largely improved 
by employing different drug delivery formulations for pharmaceuti-
cal products. Nevertheless, toxicological analysis is also required 
for these particular formulations [36]. 
 In contrast with bulk materials, nanocarriers are developed for 
their unique (surface) properties. As nanocarriers come in contact 
with bodily tissues and surfaces when administered, a toxicological 
profile of the nanocarrier employed is required. Nanocarriers could 
possess toxic properties. It may be possible to identify certain risks 
associated with the use of these nanoparticles using current tests 
and procedures [37]. 
 There are various other factors which should be taken into ac-
count with the use of nanocarriers. One of which is the stability of 
nanoparticles [38]. Nanoparticles tend to aggregate at low drug 
concentrations and the drug entrapment may vary due to polydis-
persity [39]. This will ultimately affect their efficiency and solubil-
ity in body systems. Another concern is the long-term risk of toxic-
ity with the use of nanocarriers. Nanoparticles have been said to 
affect certain physiological systems because they generate reactive 
oxygen species, which might lead to increased oxidative stress and 
induce inflammation [40,41]. However, toxicity data on the use of 
nanoparticles are conflicting [42]. Thus, more studies are needed to 
establish the toxicity of nanoparticles, to further understand their 
mechanisms and develop solutions to reduce such toxicity risks. 
 The various therapeutic applications exhibited by nanoparticles 
as a drug delivery containing phytoconstituents are discussed be-
low; 
3.1. Anticancer 
 Numerous plant-derived active constituents, like, boswellic 
acid, curcumin, vinca species, Tagetes erecta species and many 
others have been used to prevent and stop the proliferation of can-
cerous cells [7, 33,43–46]. Many studies have demonstrated that the 
active compounds present in the plants are able to show anticancer 
activity [47]. Curcumin, the polyphenol extracted from the plant 
Curcuma longa [48] was able to inhibit the proliferation and angio-
genesis of cancer cells and inducing apoptosis [32,49,50].  Studies 
have demonstrated that curcumin hindered the growth of cancer 
cells via modulation of different molecular pathways [51], such as 
activation of tumor suppressor gene (p53 and PTEN), inactivation 
of vascular endothelial growth factors (VEGF), namely, Akt and 
phosphoinositide-3-kinase (PI3K), and also by suppressing the 
production of nuclear factor-κB (NF-κB) regulated gene product 
(Fig. 2)  [49,52].   
 The main drawback is that curcumin has poor solubility and 
bioavailability. Hence poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles loaded with curcumin were developed to enhance its 
clinical uses. These nano curcumin particles have been tested on 
CaSki and SiHa cervical cancer cells and the results showed that the 
nanocurcumin could inhibit cell growth and induce apoptosis more 
 
Fig. (1). Types of nanocarriers for the delivery of therapeutic phytoconstituents. (A higher resolution / colour version of this figure is available in the elec-
tronic copy of the article). 
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effectively compared to free curcumin. The miRNA-21, nuclear β-
catenin and E6/E7 HPV oncoproteins were found to be effectively 
reduced in the orthotopic mouse model treated with nanocurcumin 
[53]. The same PLGA nanocurcumin synthesized with poly(L-
lysine) and poly(vinyl alcohol) stabilizer by using nanoprecipitation 
method has been reported to have higher cellular uptake and better 
cell proliferation suppression for both cisplatin-resistant ovarian 
cancer cells and metastatic breast cancer compared to free curcumin 
[54]. Ndong et al., produced cyclodextrin/cellulose nanocrystal 
complexes using curcumin with improved antiproliferative action 
against human prostatic and colorectal cell lines [55]. Similarly, the 
curcumin-loaded polymer-coated magnetic nanoparticles were re-
ported to be able to reduce the survival of malignant human ovarian 
carcinoma cells [56].  
 Noscapine, an alkaloid extracted from the Opium poppy, 
Papaver somniferum [1] was found to have antimitotic activity. 
This active phytoconstituent was later on tested on a mouse model, 
where it demonstrated anticancer activity in vivo against cancerous 
cell proliferation. Noscapine targets and interferes with microtubule 
formation, arrests mitosis, suppresses tumour growth and eventually 
promotes cancerous cell death [57]. Noscapine has limited clinical 
progression due to its hydrophilicity. It has a high elimination rate 
with short plasma half-life when administered intravenously, 
whereas oral administration requires a highly effective dose. Hence, 
the development of alternative formulations is necessary to improve 
the bioavailability of noscapine. Madan and colleagues constructed 
and customised noscapine solid lipid nanoparticles (SLN) conju-
gated with poly (ethylene)-glycol. This formulation showed a 
higher glioblastoma cell uptake and higher cytotoxicity with a 
lower inhibitory concentration required, in comparison with pure 
noscapine. The plasma half-life of noscapine PEG solid-lipid 
nanoparticles was 11-fold higher with a longer retention time of 
noscapine nanoparticles in mice brain. This probably would have 
been contributed by a lower volume of distribution and a lower rate 
of clearance of nanoparticles [58]. However, brominated derivatives 
of noscapine were found to have greater tubulin binding activity 
than noscapine [59]. Jyoti et al., developed nanostructured lipid 
particles loaded with noscapine analogue, 9-bromo-noscapine by 
nanoemulsion method to minimize the particles’ size down to 
100nm. This inhalable formulation exhibited improved cellular 
uptake, cancerous cell killing and apoptosis in lung cancer cell 
lines, as well as, a longer plasma half-life than 9-bromo noscapine 
nanoparticles and 9-bromo noscapine suspension [60].  
 Phytoconstituents like berberine, which could be derived from 
Coptidis rhizome, have also demonstrated suppressive effects on 
the growth of cancerous cells [61–64]. However, the poor water 
solubility of berberine makes it less effective and difficult for up-
take by the body. Thus novel delivery systems have been employed 
lately to enhance the bioavailability of berberine. For example, 
silver nanoparticles (AgNPs) were synthesized by Bhanumathi et 
al., using Syzygium cumini seed extract for the productive incorpo-
ration of berberine. The inhibitory concentration for half of the cell 
death, IC50 for berberine loaded AgNPs was lower than both the 
biogenic NPs and free berberine in MDA-MB-231 breast cancer 
cells. This novel biogenic AgNPs released berberine into breast 
cancer cells selectively and hence drug loss in the blood circulation 
was minimized [65].  Wang et al., developed SLN for the encapsu-
lation of berberine with particle size 82nm. Berberine loaded SLNs 
showed slower drug release and higher antitumor efficacy on MCF-
7 breast cancer cells when compared to free berberine [66]. Berber-
ine that is conjugated and encapsulated with dendrimers was devel-
oped and both the formulations showed excellent anti-tumour po-
tential. Gupta et al., then compared the pharmacokinetic profile of 
encapsulated and conjugated formulations in the delivery of berber-
ine using dendrimers. Results revealed that the conjugated formula-
tion showed better pharmacokinetics, higher drug load and longer 
circulation half-life compared to the encapsulated formulation [67]. 
Recently, Li et al., developed a nanocarrier for incorporating ber-
berine and miR-122 using polyethyleneimine-cholesterol (PC) with 
a particle size of 192nm. PC loaded with berberine and miR-122 
could inhibit in vitro cancer cell invasion effectively and hence 
suggested that PC is a better preferred nanocarrier for intracellular 
delivery of berberine in treating cancer [68]. 
 On the whole, these biologically degradable nanocarriers have 
unique structural and physical properties that are highly important 
in the targeted delivery of anti-cancer and image contrast agents. 
These intelligent carriers are designed to act on malignant cells, 
while, keeping healthy cells discreet. The above mentioned studies 
largely provide the current status of nanocarriers that are built as 
target-supply systems for anticancer drugs which are currently in 
clinical use. A list of nanocarriers and the type of delivery system 
currently used for the delivery of anticancer phytoconstituents is 
shown in Table 1. 
3.2. Anti-Arthritic 
 Quercetin, resveratrol and curcumin are some of the plant-based 
bioactive compounds that have been studied for their anti-arthritic 
potential. These phytoconstituents could relieve pain and swelling 
in rheumatoid arthritis by inhibiting inflammation-causing media-
tors in the body [70]. Quercetin has shown to be capable of improv-
 
Fig. (2). Role of anticancer phytoconstituents like curcumin and boswellic acid in the prevention of cancer through the inhibition of initiation, promotion, and 
progression via modulation of molecular cascades. (A higher resolution / colour version of this figure is available in the electronic copy of the article). 
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ing arthritic conditions in animal studies. It prevents inflammatory 
responses by blocking the inflammatory transcription factors from 
being generated and released into the synovial joint [71,72]. Fur-
thermore, this semi-lipophilic compound, quercetin, has been en-
capsulated into various nanosized vectors to improve its bioavail-
ability. Jeyadevi et al., developed a nanoformulation containing 
quercetin of 185nm size, composed of thioglycolic acid capped 
cadmium, quantum dots and quercetin. Quantum dots were used 
due to their unique features that could improve the target delivery 
of the drug. These nanoparticles reduced C-reactive protein and a 
rheumatoid factor, which were otherwise elevated in Wistar rats 
with arthritis in a dose-dependent manner. Thus, this study con-
cluded that employing quantum dots as nanocarriers could enhance 
the anti-arthritic effect of quercetin, as a minimal concentration of 
formulation was sufficient enough to prevent cartilage destruction 
in the rats [73]. 
 Capsaicin, a potent biomolecule, which could be extracted from 
chili pepper, was reported to reduce the pain of arthritis by acting 
deeper on the skin tissue. In order to enhance skin penetration of 
capsaicin, this lipophilic compound was encapsulated into a lipid 
vesicular system, transfersomes by Sawar et al., who evaluated 
their topical anti-arthritic potential in an experimental rat model. 
The capsaicin-loaded transfersomes were synthesized using tween 
80 and phosphatidylcholine, with a particle size of 94nm. The trans-
fersomes delivery system showed better skin penetration and a re-
quired concentration of the drug could be delivered effectively to 
the target site for treating inflammatory arthritis [74]. Furthermore, 
the same researchers used ethosomes as nanocarriers to incorporate 
capsaicin. This ethosomal delivery system exhibited pronounced 
stability with no structural changes detected after up to one year of 
storage at room temperature. Significant reduction of inflammation, 
better skin penetration along with low skin irritation were observed 
in topical ethosomal capsaicin-treated rats with arthritis [75].  
 Another potential biomolecule, piperine, exerted its antirheu-
matic activity through the inhibition of prostaglandin production 
[76]. Piperine-loaded solid lipid nanoparticles, which were synthe-
sized by melt emulsification techniques were studied for their po-
tential to treat rheumatoid arthritis. These SLNs with an average 
size of 128nm and entrapment efficiency of 78.71% were adminis-
tered into CFA-induced arthritic rats through oral and intravenous 
routes. Results showed that the formulation reduces tumor necrosis 
factor and TNF-α significantly compared to chloroquine suspen-
sion, which was the standard substance in the experiment [77]. 
Hesperidin is another plant-based compound that has a potential 
anti-rheumatic effect. Bhalekar et al., reported better disease-
modifying action of hesperidin when formulated in solid lipid 
nanoparticles. This study also demonstrated that both oral and topi-
cal SLN formulations loaded with hesperidin did not show signifi-
cant differences in in-vitro drug release, radiological analysis, 
histopathological study and tumor necrosis factor-alpha analysis 
[78]. In a recent study, hesperidin-loaded silver nanoparticles that 
were stabilized using acacia gum showed better control in tissue 
swelling of the joints and lesser joint degeneration compared to free 
hesperidin [79].   
 Curcumin, another potent biomolecule, was also able to show 
the therapeutic effect on arthritis by lowering the production of 
inflammatory mediators including, TNF-α, interleukin-1, nuclear 
factor-kappa and hypoxia-inducible factor-1α [80]. An oil in water 
nanoemulsion was formulated by Zheng et al., using a high-
pressure homogenizing method to improve the oral bioavailability 
of hydrophobic curcumin. This nanoemulsion with an average di-
ameter of 150nm exhibited better antiarthritic activity in adjuvant-
induced arthritis in rats compared to oral curcumin suspension. The 
formulation showed a threefold higher area under the curve (AUC) 
value and Cmax in bioavailability studies. The values for inhibition 
of two major cytokines, IL-1β, and TNF-α, for both oral curcumin 
nanoemulsion and intravenous curcumin solution were similar. 
However, the oral nanoemulsion showed slightly better anti-
cytokine value compared to the standard methotrexate injection. 
Hence, this study concluded that curcumin nanoemulsion could be 
an effective antirheumatic agent that could be delivered via oral 
administration [81].  Furthermore, Zhang and his colleagues formu-
lated a patient-friendly topical application of curcumin-loaded po-
lymeric nanoparticles. Their study was carried out as an in-vivo 
study. In this study, topical curcumin nanoparticles showed a potent 
effect on cartilage homeostasis. The post-traumatic osteoarthritic 
mouse treated with curcumin nanoparticles not only demonstrated 
lesser pathological changes of cartilage but also, experienced lesser 
pain associated with osteoarthritis [82]. Niazvand et al., developed 
oral curcumin nanoparticles, which were conjugated with PLGA 
Table 1. Nanocarriers for anticancer phytoconstituents. 
Bioactive  
compound  
Nanocarrier Type of delivery system Experimental model References 
PLGA based curcumin nanoparticles In-vitro/In-vivo (rats) [53] Nanoparticles 
PLGA based curcumin nanoparticles with poly(vinyl alcohol) and 
poly(L-lysine) stabilizers 
In-vitro [54] 
Nanocrystal Curcumin cyclodextrin/cellulose nanocrystal complexes In-vitro [55] 
Curcumin 
Magnetic nanoparticles Polymer-coated magnetic nanoparticles In-vitro [69] 
Nanoparticles Solid-lipid nanoparticles conjugated with poly(ethylene)-glycol In-vitro [58] Noscapine 
Lipid-based 
nanoparticles 
Nanostructured lipid nanoparticles loaded with noscapine In-vitro/In-vivo [61] 
Silver nanoparticles In-vitro/In-vivo [65] 
Solid lipid nanoparticles In-vitro/In-vivo [66] 
Nanoparticles 
Dendrimer-encapsulated and conjugated nanoparticles In-vitro/In-vivo [67] 
Berberine 
Polymeric nanoparticle Polyethyleneimine-cholesterol loaded with berberine and miR-122 In-vitro [68] 
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and evaluated their effect on monoiodoacetate-induced osteoarthri-
tis rats. These topically administered nanoparticles improved the 
matrix staining of the articular cartilage and believed nanoparticles 
might be able to penetrate into cartilage and restore matrix synthe-
sis. Overall, curcumin nanoparticles showed an enhanced chondro-
protective effect compared to free curcumin [83].  
 Nanocarriers have evolved rapidly, as the need for advanced 
therapies in inflammatory disorders emerged. These nanocarriers 
deliver a wide variety of nanomaterials and resources, that can di-
agnose and treat various inflammatory conditions. The studies dis-
cussed above focus on the present and future applications of nano-
carriers to positively treat inflammatory conditions such as arthritis, 
asthma and systemic inflammation, to name a few. It is imperative 
to use nanotechnology and nanocarriers, that may continue to stay 
as a formidable platform to solve most of the problems associated 
with the current conventional delivery methods, e.g., increased drug 
penetration into active microbial infection sites while reducing their 
side effects through drug carriers. The nanocarriers and the type of 
delivery system currently employed for the targeted delivery of 
anti-arthritic phytoconstituents are summarised in Table 2. 
3.3. Antidiabetic Effect 
 There are several nanocarriers that are currently used for the 
targeted delivery of antidiabetic phytoconstituents (Table 3). Vari-
ous investigations have shown that ingestion of phytobioactive-
compound-rich foods such as polyphenols, curcumin and 
flavanones could treat type 2 diabetes mellitus. Nevertheless, many 
food grade phytoconstituents have low solubility in water. Thus, 
several nano delivery systems are employed to improve the 
bioavailability and therapeutic effect of such plant-based antidia-
betic compounds [4,84–86].  Berberine has been found to have a 
pronounced effect in reducing blood glucose level in type 2 diabe-
tes mellitus (T2DM). It improves the glucose sensitivity of the pa-
tients by activating the insulin signaling pathway and AMP kinase-
mediated pathway [87]. Berberine has been loaded in several novel 
nano delivery systems to improve the bioavailability of berberine. 
For example, berberine-loaded solid lipid nanoparticles with an 
average particle size of 76.8nm were prepared by Xue et al., who 
evaluated their hypoglycemic effect in-vivo. SLN delivery system 
enhances the hypoglycemic effect of berberine by entrapping ber-
berine in the nanocarrier and further improves its bioavailability in 
plasma. The berberine-loaded SLNs exhibited a stronger antidia-
betic effect compared with free berberine at an equivalent dose. In 
addition, they showed a significant suppressive effect on increased 
body weight and fasting high blood glucose levels in diabetic mice 
[88]. The same researchers then found that liver is the dominant 
tissue for berberine distribution. Drug concentrations of berberine-
loaded SLNs in the liver were significantly higher than free berber-
ine. Thereby, nanoparticles accumulated in the liver were able to 
enhance lipolysis in diabetic mice [89]. In another study, a berber-
ine-loaded nanosuspension was prepared with a particle size of 
72.4nm. The formulation was studied for its oral hypoglycemic 
potential in streptozotocin-induced diabetic mice. These 
nanosuspensions were synthesized using high-pressure homogeni-
zation method to produce small desired particle size, less than 200 
nm to prolong drug circulation in blood. A higher bioavailability 
and drug plasma concentrations were observed in berberine-loaded 
nanosuspension. Thus, a lower dose of the nanosuspension was able 
to decrease blood glucose level and increase lipid metabolism in 
diabetic mice. Recently, selenium-coated nanostructured lipid car-
rier (NLC) delivery system with an average particle size of 160nm 
was developed with berberine using hot-melt disper-
sion/homogenization procedure [90]. NLC, a new generation of 
solid lipid delivery system possessed lower particle size, greater 
stability and higher drug loading over solid lipid nanoparticles. 
However, this lipid-based formulation was unable to resist them-
selves from undergoing lipolysis in the harsh environment of the 
gastrointestinal tract [91]. Hence, Yin et al., coated the NLCs with 
selenium to reinforce their stability in the gastrointestinal tract.  The 
selenium-coated NLCs demonstrated an enhanced oral bioavailabil-
ity and hypoglycemic effect which was about six-fold greater than 
berberine solution. Results also revealed that selenium-coated 
NLCs with sustained release properties could be easily taken up by 
the cells which stimulated glucose utilization by adipocytes [92].  
 Baicalin is a hydrophobic phytoconstituent which can be ex-
tracted from Scutellaria baicalensis. It has a potential therapeutic 
effect against T2DM. Multiple novel delivery systems have been 
developed to increase the solubility and oral bioavailability of bai-
calin [93]. A nano delivery system was formulated by using water, 
oil, surfactant and co-surfactant to produce nanoemulsions loaded 
with baicalin. The nanoemulsions prepared by internal and external 
addition of baicalin were compared. The findings revealed that 
there were no significant differences between the two formulations 
in terms of particle size, drug content, polydispersity index and in-
vitro release behavior. However, nanoemulsions with the internal 
addition of baicalin showed a higher AUC (0–∞) value than the 
nanoemulsion with external baicalin addition and free baicalin. The 
findings suggested that baicalin might be useful for treating various 
Table 2. Nanocarriers for anti-arthritic phytoconstituents. 
Bioactive 
compound  
Nanocarrier Type of delivery system Experimental model References 
Quercetin Quantum dot nanoparticles Glycolic-acid capped cadmium telluride quantum dots In-vitro/In-vivo [73] 
Capsaicin-loaded transfersomes  In-vivo [74] Capsaicin Lipid-based nanoparticles 
Ethosomal capsaicin In-vivo [75] 
Piperine Solid lipid nanoparticle Piperine-loaded solid lipid nanoparticle In-vivo [77] 
Solid lipid nanoparticle Hesperidin-loaded solid lipid nanoparticle In-vitro/In-vivo [78] Hesperidin 
Silver nanoparticle Hesperidin-loaded in gum acacia In-vivo [79] 
Nanoemulsion Oil-in-water nanoemulsion containing curcumin in oil phase In-vivo [81] Curcumin 
Polymeric nanoparticle Polymeric nanoparticle loaded with curcumin In-vitro/In-vivo [82] 
 Nanoparticle Curcumin-loaded PLGA nanoparticles In-vivo [83] 
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disease conditions, including T2DM [94]. In another study, Shi et 
al., developed baicalin-loaded nanostructured lipid carriers with a 
particle size of 92 nm, using a high-pressure homogenization 
method. This nanoformulation not only showed satisfactory physi-
cal stability, but also showed higher antidiabetic activity in rats 
compared to free baicalin [95]. Another approach was adopted to 
increase the oral bioavailability of baicalin by encapsulating this 
compound into liposomes. This study revealed that the nanoparti-
cles were highly accumulated in the liver and kidney [96]. Hence, it 
could be concluded that baicalin-loaded liposomal oral delivery 
system is an effective nano delivery system which could be em-
ployed to deliver drugs to target organs to treat chronic disease such 
as T2DM. 
 Another phytobioactive constituent, emodin, which can be 
found in Chinese herb rhubarb, has been reported to possess a 
therapeutic effect in T2DM [97,98]. However, its low water solubil-
ity restricts the clinical uses of the compound. Novel drug delivery 
approaches have been employed by several workers, which had 
helped to improve its bioavailability. Ren et al., prepared magne-
sium silicate hollow nanocarriers with a diameter of around 400 nm 
and evaluated their potential to inhibit angiogenesis associated with 
diabetic retinopathy, which is the main complication of T2DM. The 
nanoparticles have uniform-sized huge void space and mesoporous 
shell, allowing them to store high quantities of the drug with sus-
tained-release property. In this in-vitro study, the nanoparticles 
loaded with emodin could inhibit vascular endothelial growth factor 
effectively [99]. Nano emodin transferomes with an average parti-
cle size of 292.2 nm and encapsulation efficiency of 69.35% were 
developed to deliver emodin through the skin. Transferomes were 
chosen due to their high skin permeability, which is their ability to 
penetrate the skin barrier effectively. The findings showed an im-
proved therapeutic effect of the transdermal drug [100]. These nano 
transfersomes were prepared by Lu et al., using film-ultrasonic 
dispersion method, followed by the application of the nano 
transfersome on the abdomen of obese rats. Results showed that the 
formulation could have a significant anti-obesity effect, which 
potentially reduces the risk of T2DM [101].  
3.4. Cardioprotective Effect  
 Numerous phytoconstituents, especially those that are rich in 
antioxidant property, have been reported to have a beneficial effect 
on the cardiovascular system [102]. For example, garlic (Allium 
sativum) has been known for its anti-cardiovascular properties for 
decades [103]. It could be used to prevent or treat hyperlipidemia, 
hypertension, thrombosis and other metabolic diseases. However, 
garlic oil, the main component of garlic has low solubility in water. 
A self-nanoemulsifying system containing garlic oil was formulated 
by Phadatare et al., for improving its oral bioavailability. This for-
mulation was filled in hard gelatin capsules for easy swallow pur-
pose, which was designed to disperse to form a nanoemulsion once 
the capsule comes in contact with the gastric fluid in the stomach. 
The high surface area of small droplets of nanoemulsion enables the 
drug to be absorbed effectively and reach blood plasma for circula-
tion [104]. This self-nanoemulsifying system might be a potential 
drug delivery approach for treating hypertension. Similarly, garlic 
oil nanoemulsion with a particle size of 24.9 nm which was synthe-
sized using the ultrasonic emulsification method showed higher 
efficacy in managing dyslipidemia, the leading risk factor of car-
diovascular disease, compared to free garlic oil and atorvastatin. In 
this in-vivo study, the triglycerides, total cholesterol, low-density 
lipoprotein cholesterol and very low-density lipoprotein levels in 
the nanoemulsion-treated Wistar rats significantly reduced and their 
high-density lipoprotein cholesterol increased in a dose-dependent 
manner. Other than improved lipid-lowering potential, the nanoe-
mulsion also showed less toxicity than garlic oil with a lethal dose 
greater than 2.80ml/kg [105]. 
 Besides, grapefruit (Citrus paradisi) has been shown to have 
potent antioxidant, anticoagulant, antithrombotic and antianaemic 
effects, which is also a potentially useful agent to treat cardiovascu-
lar diseases [106,107]. Zinc oxide nanoparticles are being used 
extensively in industrial sectors dealing with production, due to 
their unique multifunctional properties. Kumar et al., synthesized 
zinc oxide nanoparticles by incorporating C. paradise peel extract 
as a stabilizer and further investigated their photocatalytic degrada-
tion and antioxidant activity. The findings from the study confirmed 
that C. paradise could fabricate nanoparticles effectively to form a 
stable nanoformulation, at the same time, the antioxidant effect of 
the phytoconstituent was also found to be enhanced [108]. The 
enhanced antioxidant activity of zinc nanoparticles containing C. 
paradise peel extract might have increased the serum antioxidant 
levels and would have contributed to cardioprotection [109].  
 The phytoconstituent curcumin that produces the yellow color 
of turmeric, has demonstrated to have significant cardioprotective 
effects [110]. A nanocrystalline-chitosan nanocarrier was used by 
Wang et al., to encapsulate demethoxycurcumin in an attempt to 
evaluate its inhibitory effect on the migration of vascular smooth 
muscle cells (VSMCs) that developed in response to arterial injury. 
This sustained-release nanoformulation with a particle size around 
150 nm inhibited the growth and migration of VSMCs 2.8 times 
more than free demethoxycurcumin [111]. Later on, Nehra et al., 
demonstrated that nanocurcumin formulation has a better preven-
tive effect on hypoxia stress in ventricular cardiomyocytes than 
curcumin. Nanocurcumin reduced the size of hypertrophied car-
diomyocytes by 38% compared to 26% in curcumin [112]. The 
same authors then used formulations combined with nanocurcumin 
Table 3. Nanocarriers for phytoconstituents used in the management of Type 2 diabetes mellitus. 
Bioactive com-
pound  
Nanocarrier Type of delivery system Experimental 
model 
References 
Solid lipid nanoparticles Berberine-loaded solid lipid nanoparticles In-vivo [87–89] Berberine 
Lipid-based nanoparticles Selenium-coated nanostructured lipid carriers In-vitro/In-vivo [90] 
Nanoemulsion Internal and external addition of baicalin In-vitro/In-vivo [93] 
Baicalin-loaded nanostructured lipid carriers In-vitro/In-vivo [94] 
Baicalin 
Lipid-based nanoparticles 
Baicalin-loaded liposomes In-vitro/In-vivo [95] 
Silica-based nanoparticles Emodin-loaded magnesium silicate hollow nanoparticle In-vitro/Ex-vivo [98] Emodin 
Lipid-based nanoparticles Emodin-loaded transfersomes In-vivo [100] 
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and pyrroloquinoline, a polyphenolic compound found in kiwi 
fruits, to study their effect against mitochondrial damage. The for-
mulation showed a higher potency in modulating cardiac hypertro-
phy than nanocurcumin or pyrroloquinoline alone [113]. Recently, 
an in-vivo study showed magnetic hydrogel nanocomposite loaded 
with curcumin that was able to show a cardioprotective effect 
against toxicity induced by doxorubicin. These uniform spherical 
nanoparticles with a mean diameter of 18-23 nm and 91% entrap-
ment efficiency exhibited greater efficacy in reducing cardiac hy-
pertrophy marker ANP, BNP and β-MHC at mRNA level compared 
to free curcumin [114,115]. Another similar study conducted by 
Quagliariello et al., evaluated the potential of nanoemulsion loaded 
with nutraceuticals (lycopene-rich tomato extract and curcumin) 
against doxorubicin-induced cardiotoxicity. The nanoemulsion 
demonstrated several molecular mechanisms in protecting the 
cardiovascular system, including modulation of ATP-dependent 
mechanisms of Mg2+ uptake and further involved in cellular inter-
nalization with actin [115]. Some of the common nanocarriers and 
the type of delivery system currently used for cardioprotective phy-
toconstituents are listed in Table 4. 
3.5. Hepatoprotective Effect 
 There has been a long history of using natural products for 
treating diseases associated with the liver [114].  Ficus Benjamina 
is one of the flowering plants that has shown prominent hepatopro-
tective activity [6,116]. Sharma et al., employed a colloidal nano-
carrier system to enhance the therapeutic effect of F. Benjamina. 
He and his team prepared SLNs loaded with the plant extract, with 
particle sizes that ranged from 20 to 50 nm and with an encapsula-
tion efficiency range of 68 to 93%. The nanoemulsion was able to 
restore the serum biomarkers including, ALP, SGOT and SGPT, 
that were previously altered by simultaneous administration of al-
cohol and disulfiram [117]. In another study, gold nanoparticles 
conjugated with garlic showed a significant hepatoprotective effect. 
The nanoformulation had a urease selective IC50 value of 180.61 
mg mL-1, which was slightly lower than the value for aqueous gar-
lic extract [118].  
 Another well-known hepatoprotective phytoconstituent, sily-
marin was incorporated in liquid nanoemulsion by using Shirasu 
porous glass membrane-emulsification method, and further by us-
ing spray-drying technique to convert these into solid nanoparticles 
for improving the delivery of less water-soluble silymarin to the 
hepatic tissue. Yang et al., formulated a nanoformulation into dry 
powder with mean sizes of 214. nm due to the poor physicochemi-
cal and physical stability of the nanoemulsion. In this in-vivo study, 
the nanoparticles containing silymarin were capable of reducings 
serum aspartate aminotransferase levels, which were elevated pre-
viously by carbon tetrachloride (CCl4), while conventional sily-
marin powder failed to reduce the elevated serum aspartate 
aminotransferase levels. Furthermore, the oral bioavailability of 
nanoparticles was 1.3 times greater than the silymarin powder 
[119]. Recently, Ahmad et al., developed and optimized stable 
silymarin nanoemulsion using the aqueous titration method. The 
nanoemulsion made up of 5.0% of oil, 28.99% of a mixture of sur-
factant and co-surfactant and 65.22% of water appeared to have the 
smallest particle size, which was around 21.24 nm. The optimized 
formulation was further evaluated for its potential activity against 
hepatocellular carcinoma. The findings revealed that the formula-
tion was able to increase the generation of reactive oxygen species 
to kill liver carcinoma cells without affecting the healthy cells 
[120]. In another study, bilisomes loaded with silymarin with an 
average diameter range from 413 to 686 nm were prepared using 
thin-film hydration technique [121]. Bilosomes were used as nano-
carriers in this study due to their benefit of bile salts that were con-
tained in the liposomes, which were able to assist in the delivery of 
the lipophilic drug across the cellular membrane and hence increas-
ing the oral bioavailability of the silymarin [122]. Bilosomes loaded 
with silymarin have shown the highest hepatoprotective effect and 
also the highest restoring effect in CCl4 induced liver cell damage 
compared to free silymarin and marketed silymarin product, Le-
galon®. Silymarin-loaded bilosomes showed a more pronounced 
effect in reducing alanine aminotransferase and aspartate 
aminotransferase compared to silymarin-loaded liposomes [121]. 
Various nanocarriers currently employed for the delivery of hepa-
toprotective phytoconstituents are summarised in Table 5. 
CONCLUSION 
 Plant-based bioactive compounds have shown prominent poten-
tial in preventing or treating various types of chronic diseases, in-
cluding type 2 diabetes mellitus, cardiovascular disease, arthritis, 
hepatic disease and cancer. However, their clinical uses have been 
limited due to their poor water solubility, low stability in-vivo, low 
absorption and low bioavailability. Hence, nanocarriers are em-
ployed to overcome such barriers to improve solubility and stability 
of phytoconstituents, to enhance their absorption and reduce their 
toxicity, which are achieved by reducing their particle sizes and by 
modifying their surface properties. Nanocarriers have thus provided 
crucial steps in bringing medicinal phytoconstituents closer to their 
clinical demand. However, additional studies are required to assess 
and improve the long-term safety of nanosized phytoconstituents to 
further enhance their use in biomedicine.  
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Table 4. Nanocarriers for cardioprotective phytoconstituents. 
Bioactive compound  Nanocarrier Type of delivery system Experimental model References 
Self-nano emulsifying system loaded with garlic In-vitro/Ex-vivo [103] Allium sativum Nanoemulsions 
Garlic oil-loaded nanoemulsion In-vivo [104] 
Grapefruit Nanoparticles Grapefruit-loaded zinc oxide nanoparticles In-vitro [107] 
Nanocrystalline-chitosan nanoparticles In-vitro [110] 
Curcumin-loaded nanoparticles In-vitro [111] 
Curcumin Nanoparticles 
Curcumin-loaded magnetic hydrogel nanocomposite In-vitro/In-vivo [113] 
Curcumin and lycopene Nanoemulsion Oil-in-water nanoemulsion containing curcumin and 
lycopene in oil phase 
In-vitro [114] 
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